14.1 Contraceptive Management, Emergency Contraception & Preconception Counseling
Key Takeaways
- The CDC United States Medical Eligibility Criteria for Contraceptive Use (US MEC) classifies safety from Category 1 (no restriction) to Category 4 (unacceptable health risk/absolute contraindication); Combined Hormonal Contraceptives (CHCs) are US MEC 4 in women ≥35 who smoke ≥15 cigarettes/day, migraine with aura at any age, uncontrolled hypertension (≥160/100 mmHg), active or history of DVT/PE, ischemic heart disease, and active breast cancer.
- Long-Acting Reversible Contraception (LARC)—including levonorgestrel IUDs, the copper T380A IUD, and subdermal etonogestrel implants—represents Tier 1 contraceptive efficacy with typical failure rates <1%, operating independent of daily user compliance.
- Depot Medroxyprogesterone Acetate (DMPA) carries a Black Box Warning for reversible loss of bone mineral density (BMD); routine DEXA monitoring is not recommended for asymptomatic users, but patients must be counseled on adequate calcium/vitamin D intake and weight-bearing exercise.
- Emergency contraception options must be selected based on time elapsed since unprotected coitus and patient BMI: Copper T380A and 52 mg LNG IUDs are >99% effective up to 5 days regardless of BMI; Ulipristal acetate (Ella 30 mg) maintains superior oral efficacy up to 120 hours and in BMI 26–35 kg/m²; Levonorgestrel (Plan B 1.5 mg) is FDA-approved up to 72 hours with diminished efficacy in BMI ≥25–30 kg/m².
- Preconception counseling requires universal daily folic acid supplementation (400 mcg for average-risk; 4,000 mcg [4 mg] for high-risk neural tube defect history or antiepileptic drug use), stringent teratogenic medication cessation (ACE inhibitors, ARBs, statins, valproate, methotrexate, isotretinoin), optimization of chronic maternal disease (HbA1c <6.5% in pregestational diabetes), and confirmation of rubella and varicella immunity prior to conception.
Last updated: August 2026
Contraceptive Management, Emergency Contraception & Preconception Counseling
Contraceptive selection and preconception optimization in adult-gerontology primary care require advanced knowledge of reproductive physiology, endocrine pharmacology, teratology, and evidence-based clinical safety frameworks. The Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP) manages contraceptive care from post-menarche through the menopausal transition, balancing patient autonomy and reproductive goals against complex cardiovascular, metabolic, and thrombotic comorbidities.
1. CDC US Medical Eligibility Criteria (US MEC) Framework
The Centers for Disease Control and Prevention (CDC) U.S. Medical Eligibility Criteria for Contraceptive Use (US MEC) provides the evidence-based gold standard for evaluating contraceptive safety across hundreds of underlying clinical conditions.
+---------------------------------------------------------------------------------------------------+
| CDC US MEC CONTRACEPTIVE SAFETY CLASSIFICATION |
| |
| CATEGORY 1 - A condition for which there is NO RESTRICTION for the use of the method. |
| (Safe for all patients without caveat). |
| |
| CATEGORY 2 - A condition where the ADVANTAGES GENERALLY OUTWEIGH theoretical or proven risks.|
| (Method can generally be used; routine clinical follow-up). |
| |
| CATEGORY 3 - A condition where theoretical or proven RISKS USUALLY OUTWEIGH the advantages. |
| (Method NOT recommended unless other methods are unavailable or unacceptable). |
| |
| CATEGORY 4 - A condition that represents an UNACCEPTABLE HEALTH RISK. |
| (ABSOLUTE CONTRAINDICATION: Method must NOT be initiated or used). |
+---------------------------------------------------------------------------------------------------+
Hallmark US MEC Category 4 Contraindications for Combined Hormonal Contraceptives (CHCs)
Combined Hormonal Contraceptives (combined oral contraceptive pills [COCs], transdermal patch, and contraceptive vaginal ring) contain ethinyl estradiol (EE) or estetrol combined with a synthetic progestin. Estrogen enhances hepatic synthesis of coagulation factors (Factors II, VII, VIII, X, and fibrinogen) while downregulating antithrombin III and protein S. Therefore, CHCs are strictly US MEC Category 4 (Absolute Contraindication) in the following clinical scenarios:
+---------------------------------------------------------------------------------------------------+
| ABSOLUTE CONTRAINDICATIONS (US MEC CATEGORY 4) FOR CHCs |
| |
| 1. VASCULAR & THROMBOEMBOLIC DISEASE: |
| - Current or past history of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) |
| - Known thrombogenic mutations (Factor V Leiden, Prothrombin G20210A mutation, Protein C, |
| Protein S, or Antithrombin deficiency) |
| - Major surgery with prolonged immobilization |
| - Current or personal history of Ischemic Heart Disease (CAD, prior MI, angina) |
| - History of Cerebrovascular Accident (Ischemic or Hemorrhagic Stroke) |
| - Valvular heart disease complicated by pulmonary hypertension, atrial fibrillation, or |
| subacute bacterial endocarditis |
| |
| 2. AGE & TOBACCO USE: |
| - Age ≥35 years AND currently smoking ≥15 cigarettes per day |
| (Note: Age ≥35 smoking <15 cigarettes/day is US MEC Category 3) |
| |
| 3. NEUROLOGICAL: |
| - Migraine headache WITH AURA at any age (markedly elevates ischemic stroke risk) |
| |
| 4. HYPERTENSION: |
| - Systolic BP ≥160 mmHg OR Diastolic BP ≥100 mmHg, or hypertension with vascular disease |
| (Adequately controlled HTN on medication is US MEC 3) |
| |
| 5. ONCOLOGIC & HEPATIC: |
| - Current or past personal history of Breast Cancer (estrogen-dependent neoplasm) |
| - Severe decompensated cirrhosis, hepatocellular adenoma, or malignant liver tumors |
| - Acute viral hepatitis (until liver function tests normalize) |
| |
| 6. METABOLIC & POSTPARTUM: |
| - Diabetes mellitus with microvascular complications (nephropathy, retinopathy, neuropathy) |
| or diabetes of >20 years duration |
| - Postpartum <21 days (elevated hypercoagulability regardless of breastfeeding status) |
+---------------------------------------------------------------------------------------------------+
| Clinical Characteristic | CHCs (COCs / Patch / Ring) | DMPA (Depo-Provera) | Nexplanon (Implant) | LNG-IUD (Mirena) | Copper IUD (ParaGard) |
|---|---|---|---|---|---|
| Age ≥35, Smoker ≥15 cig/day | MEC 4 | MEC 1 | MEC 1 | MEC 1 | MEC 1 |
| Migraine with Aura (any age) | MEC 4 | MEC 2 | MEC 2 | MEC 2 | MEC 1 |
| History of DVT / PE (not on AC) | MEC 4 | MEC 2 | MEC 2 | MEC 2 | MEC 1 |
| Severe Hypertension (≥160/100) | MEC 4 | MEC 2 | MEC 1 | MEC 1 | MEC 1 |
| Current Active Breast Cancer | MEC 4 | MEC 4 | MEC 4 | MEC 4 | MEC 1 |
| Current Purulent Cervicitis/PID | MEC 1 | MEC 1 | MEC 1 | MEC 4 (for insertion) | MEC 4 (for insertion) |
| Systemic Lupus (Positive aPL) | MEC 4 | MEC 3 | MEC 3 | MEC 3 | MEC 1 |
| Diabetes with Retinopathy/Nephr | MEC 4 | MEC 2 | MEC 2 | MEC 2 | MEC 1 |
| Bariatric Malabsorptive Surgery | MEC 3 (Pills only) | MEC 1 | MEC 1 | MEC 1 | MEC 1 |
Clinical Pearl: Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin antibodies) confer massive thromboembolic risk; all systemic hormonal methods containing estrogen are MEC 4, progestin methods are MEC 3, and Copper IUD is MEC 1.
2. Contraceptive Modalities & Clinical Pharmacology
+---------------------------------------------------------------------------------------------------+
| TIERED CONTRACEPTIVE EFFICACY PYRAMID |
| |
| [TIER 1: MOST EFFECTIVE (<1% Typical Failure)] |
| - Etonogestrel Subdermal Implant (Nexplanon): ~0.05% failure |
| - Levonorgestrel IUD (Mirena, Kyleena, Liletta, Skyla): 0.1 - 0.2% failure |
| - Copper T380A IUD (ParaGard): 0.6 - 0.8% failure |
| - Permanent Tubal Occlusion / Bilateral Salpingectomy: ~0.5% failure |
| - Vasectomy: 0.15% failure |
| |
| [TIER 2: HIGHLY EFFECTIVE (4 - 9% Typical Failure - User Compliance Dependent)] |
| - Depot Medroxyprogesterone Acetate (DMPA Injection q12 weeks): ~4% failure |
| - Combined Oral Contraceptive Pills (COCs): ~7% failure |
| - Progestin-Only Pills (POPs / Mini-pill): ~7% failure |
| - Transdermal Contraceptive Patch (weekly): ~7% failure |
| - Contraceptive Vaginal Ring (monthly or annual): ~7% failure |
| |
| [TIER 3: MODERATELY EFFECTIVE (12 - 24% Typical Failure - Strict Coital Compliance)] |
| - Male Latex / Polyurethane Condoms: 13% failure (Essential for STI prevention!) |
| - Female Condoms: 21% failure |
| - Diaphragm with Spermicide: 17% failure (Must remain in place ≥6 hrs post-coitus; max 24 hrs) |
| - Fertility Awareness-Based Methods (FABM): 15 - 24% failure |
| - Withdrawal (Coitus Interruptus): 20% failure |
| - Spermicide (Nonoxynol-9 alone): 21 - 28% failure |
+---------------------------------------------------------------------------------------------------+
A. Long-Acting Reversible Contraceptives (LARC) - Tier 1
LARCs do not depend on patient adherence and provide multi-year protection. They are first-line recommendations for adolescents, nulliparous women, and adults seeking high efficacy.
1. Levonorgestrel Intrauterine Devices (LNG-IUDs)
- Available Devices:
- Mirena (52 mg LNG; releases 20 mcg/day; FDA-approved up to 8 years; approved for heavy menstrual bleeding).
- Liletta (52 mg LNG; approved up to 8 years).
- Kyleena (19.5 mg LNG; releases 17.5 mcg/day down to 7.4 mcg/day; smaller frame; approved up to 5 years).
- Skyla (13.5 mg LNG; releases 14 mcg/day; smallest frame; approved up to 3 years).
- Mechanisms of Action: Thickens cervical mucus to impede sperm penetration; induces endometrial glandular atrophy and stromal decidualization; impairs sperm motility and viability via foreign body sterile inflammatory response; partially inhibits ovulation in first year (though systemic absorption is minimal).
- Bleeding Changes: Irregular spotting and light bleeding in first 3–6 months, progressively transitioning to amenorrhea (20–50% at 1 year for 52 mg devices) or oligomenorrhea.
- Non-Contraceptive Indications: Idiopathic heavy menstrual bleeding (menorrhagia), dysmenorrhea, endometrial hyperplasia prevention in menopausal therapy, and pelvic pain associated with endometriosis.
2. Non-Hormonal Copper T380A IUD (ParaGard)
- Mechanism of Action: Continuous release of copper ions ($Cu^{2+}$) into the uterine cavity produces a localized, sterile, non-infectious inflammatory response. Copper ions are directly toxic to sperm (inhibits sperm motility, acrosome reaction, and capacitation) and prevent blastocyst implantation.
- Duration: FDA-approved for 10 years (evidence supports efficacy up to 12 years).
- Bleeding Changes: Menstrual menses may be 30–50% heavier with increased cramping/dysmenorrhea, particularly during cycles 1–3. Managed with scheduled NSAIDs (e.g., mefenamic acid or naproxen) during menses.
- US MEC 4 Contraindications: Uterine cavity distortion (bicornuate uterus, large submucosal leiomyoma), unexplained abnormal uterine bleeding prior to evaluation, acute purulent cervicitis/PID (active infection), known Wilson's disease, or copper allergy.
3. Subdermal Etonogestrel Implant (Nexplanon)
- Formulation & Mechanism: Single semi-rigid rod containing 68 mg etonogestrel placed subdermally in the inner non-dominant upper arm. Suppresses the mid-cycle LH surge to prevent ovulation; thickens cervical mucus; atrophies the endometrium.
- Duration: FDA-approved for 3 years (robust clinical data supports efficacy up to 5 years).
- Primary Side Effect Profile: Unpredictable, unscheduled bleeding/spotting is the most common reason for premature discontinuation (~11%). Patients must be counseled that amenorrhea occurs in ~20%, but prolonged bleeding or irregular spotting may occur throughout use. Unscheduled bleeding can be managed short-term with a 3–5 day course of scheduled NSAIDs (mefenamic acid 500 mg TID or ibuprofen 800 mg TID) or a 10–21 day bridge of low-dose combined oral contraceptives or oral estrogen (if no contraindications).
B. Progestin Injection: Depot Medroxyprogesterone Acetate (DMPA / Depo-Provera)
- Dosing & Administration: 150 mg IM (gluteal or deltoid) or 104 mg SubQ every 12 to 13 weeks (re-injection window up to 15 weeks without requiring backup or pregnancy testing if negative).
- Mechanism: High-dose systemic progestin exerts negative feedback on hypothalamic GnRH, suppressing pituitary FSH and LH secretions to block ovulation completely; creates dense cervical mucus.
- Clinical Considerations & Board Pearls:
- Delayed Return to Fertility: Median time to conception post-discontinuation is 9 to 10 months (can take up to 18 months). Do not recommend to women desiring pregnancy within the next 12 months.
- Weight Gain: The only hormonal contraceptive consistently linked to documented weight gain (average 2–5 kg over 1–2 years due to appetite stimulation).
- Amenorrhea: Occurs in 50% of users by 12 months and 70% by 2 years.
- Bone Mineral Density (BMD) Black Box Warning: DMPA suppresses ovarian estradiol production, leading to reversible bone mineral density loss. The FDA Black Box Warning advises against use for >2 years unless other methods are unacceptable. However, major professional organizations (ACOG, CDC, AAP) state that DMPA should NOT be restricted to 2 years in individuals who find it effective, because bone loss is substantially or fully reversible after cessation. Routine DEXA screening is NOT indicated in healthy adolescents and adults on DMPA. Counsel on 1,200 mg elemental calcium and 800–1,000 IU Vitamin D daily plus weight-bearing exercise.
C. Combined Hormonal Contraceptives (CHCs): Pills, Patch, Ring
- Combined Oral Contraceptives (COCs): Contain ethinyl estradiol (EE, typically 10–35 mcg) plus a progestin. Progestins are grouped into generations:
- 1st Generation: Norethindrone, ethynodiol diacetate (mild androgenic activity).
- 2nd Generation: Levonorgestrel, norgestrel (most androgenic; lowest VTE risk among all progestins; preferred initial choice for general patients without acne concerns).
- 3rd Generation: Desogestrel, norgestimate (lower androgenic activity, excellent for acne/hirsutism; slightly higher relative VTE risk compared to 2nd gen).
- 4th Generation: Drospirenone (spironolactone analog with antimineralocorticoid and antiandrogenic properties). Excellent for acne, hirsutism, and PMDD. Monitoring: Can cause hyperkalemia; caution if co-prescribed with ACE inhibitors, ARBs, or potassium-sparing diuretics.
- Transdermal Contraceptive Patch (Xulane, Zafemy, Twirla): Applied weekly for 3 consecutive weeks, followed by 1 patch-free week. Decreased contraceptive efficacy in individuals weighing $\ge 90\text{ kg}$ (198 lbs) or $\text{BMI} \ge 30\text{ kg/m}^2$. Twirla is contraindicated in $\text{BMI} \ge 30\text{ kg/m}^2$.
- Vaginal Rings:
- NuvaRing: Ethinyl estradiol + etonogestrel ring inserted intravaginally for 3 weeks, removed for 1 week. If expelled for $>3\text{ hours}$, reinsert and use backup barrier contraception for 7 days.
- Annovera: Reusable segesterone acetate + ethinyl estradiol ring washed and reused monthly for 1 full year (13 cycles: 21 days in, 7 days out).
+---------------------------------------------------------------------------------------------------+
| PATIENT EDUCATION: ACHES WARNING SIGNS FOR CHCs |
| |
| A - ABDOMINAL PAIN (Severe) -> Mesenteric vein thrombosis, hepatic adenoma, pancreatitis |
| C - CHEST PAIN / DYSPNEA -> Pulmonary embolism (PE) or Acute Myocardial Infarction |
| H - HEADACHE (Severe, throbbing) -> Stroke, hypertensive emergency, or retinal migraine |
| E - EYE PROBLEMS (Blurring/loss) -> Retinal artery or vein thrombosis |
| S - SEVERE LEG PAIN / SWELLING -> Deep Vein Thrombosis (DVT) |
+---------------------------------------------------------------------------------------------------+
D. Missed Combined Oral Contraceptive Protocols (CDC SPR Guidelines)
+---------------------------------------------------------------------------------------------------+
| CDC SELECTED PRACTICE RECOMMENDATIONS: MISSED COCs |
| |
| [ONE PILL MISSED (<24 - 48 HOURS LATE)] |
| - Take the missed pill IMMEDIATELY. |
| - Take the next pill at the regular scheduled time (even if 2 pills taken on the same day). |
| - No backup contraception required. Emergency contraception (EC) generally not needed. |
| |
| [TWO OR MORE CONSECUTIVE PILLS MISSED (≥48 HOURS LATE)] |
| - Take the MOST RECENT missed pill IMMEDIATELY; discard remaining earlier missed pills. |
| - Continue taking remaining active pills on normal daily schedule. |
| - MUST USE BACKUP BARRIER CONTRACEPTION (condoms) or abstain for 7 CONSECUTIVE DAYS. |
| - If pills missed in WEEK 3 (Pills 15-21 of a 28-day pack): |
| * Complete the active pills in the current pack. |
| * DISCARD the hormone-free placebo pills completely. |
| * Start a NEW active pack the very next day without taking the 7-day placebo break. |
| - If unprotected intercourse occurred in the preceding 5 days, consider Emergency Contraception.|
+---------------------------------------------------------------------------------------------------+
E. Progestin-Only Pills (POPs / "Mini-Pills")
- Traditional POPs (Norethindrone 0.35 mg): Primary mechanism is thickening cervical mucus (which peaks at 4 hours and wanes at 20–24 hours). Does not reliably suppress ovulation (~50% ovulate). Strict Dosing Window: Must be taken at the exact same hour daily. If taken $>3\text{ hours}$ late, patient must take the pill immediately, resume regular schedule, and use backup barrier contraception for 48 hours.
- Novel POPs (Drospirenone 4 mg - Slynd): 24 active / 4 placebo schedule. Reliable ovulation suppression with a 24-hour missed pill window, matching COC flexibility without estrogen-related VTE risks.
3. Emergency Contraception (EC)
Emergency contraception is indicated following unprotected intercourse, sexual assault, condom slippage/breakage, or $\ge 2$ missed active hormonal pills.
+---------------------------------------------------------------------------------------------------+
| EMERGENCY CONTRACEPTION MODALITIES MATRIX |
| |
| METHOD TIMING WINDOW EFFICACY BMI CONSIDERATIONS |
| --------------------------------------------------------------------------------------------- |
| 1. Copper T380A IUD 0 - 120 hrs (5 d) >99.9% (Best) Efficacious in all BMI classes |
| 2. 52 mg LNG-IUD 0 - 120 hrs (5 d) >99.7% Efficacious in all BMI classes |
| 3. Ulipristal (Ella) 0 - 120 hrs (5 d) ~98% Superior to LNG in BMI >25 kg/m²; |
| 30 mg oral (SPRM) Maintains efficacy in BMI 26-35 |
| 4. Levonorgestrel 0 - 72 hrs (3 d)* ~85 - 89% Diminished efficacy in BMI ≥25; |
| 1.5 mg (Plan B) *(Up to 120 hrs) Ineffective in BMI ≥30 kg/m² |
+---------------------------------------------------------------------------------------------------+
Detailed Pharmacological Comparison: Ulipristal vs. Levonorgestrel
- Ulipristal Acetate (Ella, 30 mg oral single dose):
- Mechanism: Selective Progesterone Receptor Modulator (SPRM). Delays follicular rupture and ovulation even when the luteinizing hormone (LH) surge has already started (effective up to the LH peak).
- Prescription Status: Requires a prescription.
- Critical Drug Interaction Pearl: Because ulipristal is a progesterone receptor modulator, starting progestin-containing birth control immediately after taking Ella reduces Ella's efficacy and vice versa. Patients must WAIT 5 FULL DAYS after taking Ella before starting or resuming hormonal contraception, and must use backup barrier contraception until their next menses.
- Levonorgestrel (Plan B One-Step, 1.5 mg oral single dose):
- Mechanism: High-dose synthetic progestin that prevents or delays the LH surge. Ineffective once the LH surge has begun and ineffective post-ovulation.
- Availability: Available over-the-counter (OTC) without age restriction or prescription.
- Hormonal Quick Start: Regular hormonal contraception can be started immediately ("Quick Start") on the same day. Patient must use backup barrier contraception for 7 days.
4. "Quick Start" Initiation & Backup Contraception Protocols
Under CDC Selected Practice Recommendations, patients can start any contraceptive method on the same day as their office visit if the clinician is reasonably certain the patient is not pregnant.
+---------------------------------------------------------------------------------------------------+
| CDC CRITERIA: REASONABLY CERTAIN A PATIENT IS NOT PREGNANT |
| |
| A clinician is reasonably certain a patient is not pregnant if they have no signs/symptoms of |
| pregnancy AND meet AT LEAST ONE of the following: |
| 1. ≤7 days after the start of normal menses. |
| 2. No sexual intercourse since the start of last normal menses. |
| 3. Correctly and consistently using a reliable contraceptive method. |
| 4. ≤7 days after spontaneous or induced abortion. |
| 5. ≤4 weeks postpartum. |
| 6. Fully or nearly fully breastfeeding (amenorrheic and <6 months postpartum). |
+---------------------------------------------------------------------------------------------------+
+---------------------------------------------------------------------------------------------------+
| BACKUP CONTRACEPTION DURATION RULES |
| |
| METHOD INITIATED CYCLE DAY INITIATED BACKUP METHOD REQUIRED? |
| --------------------------------------------------------------------------------------------- |
| Combined OCPs / Patch / Ring Days 1 - 5 of menses NO backup needed |
| Combined OCPs / Patch / Ring Any other day ("Quick Start") YES: Use backup for 7 DAYS |
| Progestin-Only Pill (Noreth.) Any day of cycle YES: Use backup for 48 HOURS |
| DMPA (Depo Injection) Days 1 - 7 of menses NO backup needed |
| DMPA (Depo Injection) Any other day YES: Use backup for 7 DAYS |
| Nexplanon (Implant) Days 1 - 5 of menses NO backup needed |
| Nexplanon (Implant) Any other day YES: Use backup for 7 DAYS |
| Levonorgestrel IUD Days 1 - 7 of menses NO backup needed |
| Levonorgestrel IUD Any other day YES: Use backup for 7 DAYS |
| Copper T380A IUD ANY DAY of menstrual cycle NO backup needed (Immediate!) |
+---------------------------------------------------------------------------------------------------+
5. Comprehensive Preconception Counseling & Risk Optimization
Preconception health counseling aims to identify biomedical, behavioral, and social risks to a woman's health and future pregnancy outcomes through prevention and management.
+---------------------------------------------------------------------------------------------------+
| PRECONCEPTION CLINICAL OPTIMIZATION CHECKLIST |
| |
| [1. FOLIC ACID SUPPLEMENTATION] |
| - Average Risk: 400 mcg (0.4 mg) daily starting ≥1 month prior to conception to prevent neural |
| tube defects (anencephaly, spina bifida). (USPSTF Grade A). |
| - High Risk: 4,000 mcg (4.0 mg) daily starting ≥3 months prior to conception: |
| * Personal or prior pregnancy history of neural tube defect (NTD) |
| * Current antiepileptic drug use (valproate, carbamazepine) |
| * Pregestational Type 1 or Type 2 Diabetes Mellitus |
| * Malabsorptive bariatric surgery or active inflammatory bowel disease (Crohn's / Celiac) |
| |
| [2. TERATOGENIC MEDICATION RECONCILIATION] |
| - Discontinue ACE inhibitors & ARBs -> Oligohydramnios, fetal renal agenesis, pulmonary hypoplas|
| - Discontinue Statins (HMG-CoA reductase inhibitors) -> Discontinue prior to conception |
| - Discontinue Methotrexate -> Skeletal dysmorphism, neural tube defects, miscarriage |
| - Discontinue Valproic Acid / Carbamazepine -> Switch to Levetiracetam or Lamotrigine |
| - Discontinue Warfarin -> Fetal warfarin syndrome (nasal hypoplasia, stippled epiphyses) |
| (Switch to Therapeutic LMWH / Enoxaparin prior to or immediately upon conception) |
| - Discontinue Isotretinoin -> Severe craniofacial, cardiac, and thymic malformations |
| |
| [3. CHRONIC DISEASE METABOLIC TARGETS] |
| - Diabetes: Achieve HbA1c <6.5% before conception to prevent sacral agenesis and cardiac defect|
| - Hypertension: Transition to safe antihypertensives (Labetalol, Nifedipine ER, Methyldopa) |
| - Hypothyroidism: Optimize pre-pregnancy TSH <2.5 mIU/L (anticipate 30-50% dose increase in T1)|
| - Phenylketonuria (PKU): Strict low-phenylalanine diet (target Phe <6 mg/dL) to prevent fetal |
| microcephaly and intellectual disability |
| |
| [4. INFECTIOUS SCREENING & IMMUNIZATIONS] |
| - Rubella & Varicella IgG: Screen titers. If non-immune, administer MMR and/or Varicella vaccine|
| and advise pregnancy avoidance for AT LEAST 28 DAYS (4 WEEKS) post-vaccination (Live Virus!).|
| - Hepatitis B, HIV, Syphilis (RPR/VDRL), Chlamydia, Gonorrhea screening |
| - Administer Inactivated Influenza and updated COVID-19 vaccines (Safe in any trimester) |
| - Note: Tdap is administered at 27-36 weeks gestation during EACH pregnancy (passive pertussis) |
+---------------------------------------------------------------------------------------------------+
6. Board-Yield Summary & Clinical Pearls
+---------------------------------------------------------------------------------------------------+
| ANCC AGPCNP CLINICAL EXAM PEARLS |
| |
| - Never prescribe Combined Hormonal Contraceptives (COCs, patch, ring) to a woman ≥35 who |
| smokes ≥15 cigarettes/day or ANY patient with migraine with aura (MEC 4: Stroke/VTE risk!). |
| |
| - Copper T380A IUD and 52 mg LNG-IUDs are the most effective emergency contraceptives and are |
| unaffected by elevated body mass index (BMI). |
| |
| - If prescribing Ulipristal (Ella) for emergency contraception, warn the patient to delay |
| starting hormonal birth control for exactly 5 days; if using Levonorgestrel (Plan B), start |
| hormonal birth control immediately. |
| |
| - Live vaccines (MMR, Varicella) are STRICTLY CONTRAINDICATED during pregnancy; if administered |
| preconceptionally, the patient must wait at least 4 weeks (28 days) before attempting |
| conception. |
| |
| - High-dose folic acid (4 mg / 4,000 mcg daily) is mandatory for patients on valproate or with |
| a prior pregnancy affected by a neural tube defect. |
+---------------------------------------------------------------------------------------------------+
Test Your Knowledge
A 36-year-old female presents to the primary care clinic seeking reliable contraception. Her past medical history is significant for migraines without aura and mild well-controlled asthma. She reports smoking 1 pack of cigarettes daily (20 cigarettes/day) for the past 14 years. Blood pressure is 122/76 mmHg, heart rate is 72 bpm, and BMI is 24.8 kg/m². Which contraceptive method is categorized as US MEC Category 4 (Unacceptable Health Risk / Absolutely Contraindicated) for this patient?
A
B
C
D
Test Your Knowledge
A 24-year-old female presents for emergency contraception after experiencing condom breakage during intercourse 36 hours ago. Her BMI is 32.4 kg/m². She takes no daily medications and has no chronic medical conditions. She desires an oral emergency contraceptive and requests guidance on when she can restart her daily combined oral contraceptive pills. Which oral emergency contraceptive regimen and initiation counseling should the AGPCNP provide?
A
B
C
D
Test Your Knowledge
A 28-year-old nulliparous female presents for preconception counseling. Her medical history is significant for generalized tonic-clonic epilepsy well-controlled on valproic acid 500 mg twice daily. Her last seizure occurred 3 years ago. Routine preconception laboratory testing reveals a non-immune Rubella IgG antibody titer. What combination of clinical actions is the most appropriate management plan for this patient?
A
B
C
D